PL363869A1 - Środki lecznicze do zapobiegania i leczenia chorób neurozwyrodnieniowych - Google Patents

Środki lecznicze do zapobiegania i leczenia chorób neurozwyrodnieniowych

Info

Publication number
PL363869A1
PL363869A1 PL01363869A PL36386901A PL363869A1 PL 363869 A1 PL363869 A1 PL 363869A1 PL 01363869 A PL01363869 A PL 01363869A PL 36386901 A PL36386901 A PL 36386901A PL 363869 A1 PL363869 A1 PL 363869A1
Authority
PL
Poland
Prior art keywords
medicines
prevention
treatment
neurodegenerative diseases
neurodegenerative
Prior art date
Application number
PL01363869A
Other languages
English (en)
Other versions
PL200537B1 (pl
Inventor
Kiyoshi Furukawa
Satoshi Kurumiya
Kazuo Okimoto
Kazunori Ohno
Original Assignee
Dainippon Pharmaceutical Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co, Ltd. filed Critical Dainippon Pharmaceutical Co, Ltd.
Publication of PL363869A1 publication Critical patent/PL363869A1/pl
Publication of PL200537B1 publication Critical patent/PL200537B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL363869A 2000-06-21 2001-06-12 Środek leczniczy do zapobiegania i leczenia schizofrenii oraz zastosowanie PL200537B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000185814 2000-06-21
PCT/JP2001/004934 WO2001098300A1 (en) 2000-06-21 2001-06-12 Medicines for the prevention and treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
PL363869A1 true PL363869A1 (pl) 2004-11-29
PL200537B1 PL200537B1 (pl) 2009-01-30

Family

ID=18686074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL363869A PL200537B1 (pl) 2000-06-21 2001-06-12 Środek leczniczy do zapobiegania i leczenia schizofrenii oraz zastosowanie

Country Status (19)

Country Link
US (1) US6743803B2 (pl)
EP (1) EP1295883A4 (pl)
KR (1) KR20030010740A (pl)
CN (1) CN100354274C (pl)
AU (2) AU6274101A (pl)
BR (1) BR0111799A (pl)
CA (1) CA2412199A1 (pl)
CZ (1) CZ20024153A3 (pl)
EE (1) EE04941B1 (pl)
HU (1) HUP0301319A3 (pl)
IL (2) IL153439A0 (pl)
MX (1) MXPA02012599A (pl)
NO (1) NO20026148L (pl)
NZ (1) NZ523189A (pl)
PL (1) PL200537B1 (pl)
RU (1) RU2258506C2 (pl)
SK (1) SK17682002A3 (pl)
TW (1) TWI298068B (pl)
WO (1) WO2001098300A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
WO2010002451A1 (en) * 2008-07-01 2010-01-07 Concert Pharmaceuticals, Inc. Naphthyridin derivatives
JP6551671B2 (ja) * 2015-08-11 2019-07-31 国立大学法人 熊本大学 アルツハイマー治療薬
IL289891B2 (en) * 2019-07-18 2025-06-01 Abaxys Therapeutics Solid formulation of a 1,2,4-oxadiazole derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683818B1 (fr) 1991-11-14 1993-12-31 Adir Cie Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU664912B2 (en) * 1992-09-02 1995-12-07 Dainippon Pharmaceutical Co. Ltd. Novel 3-oxadiazolyl-1,6-naphthyridine derivatives
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
ZA985870B (en) * 1997-07-15 1999-01-27 Dainippon Pharmaceutical Co 5-substituted-3-oxadiazolyl-1, 6-naphthyridin-2(1H)-one derivatives
BE1011286A3 (fr) * 1997-07-17 1999-07-06 Magotteaux Int Broyeur rotatif.
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
CH1196397H1 (de) 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.

Also Published As

Publication number Publication date
CZ20024153A3 (cs) 2003-06-18
CA2412199A1 (en) 2001-12-27
IL153439A0 (en) 2003-07-06
AU2001262741B2 (en) 2005-07-07
IL153439A (en) 2007-07-24
KR20030010740A (ko) 2003-02-05
US20030166673A1 (en) 2003-09-04
NO20026148D0 (no) 2002-12-20
EE04941B1 (et) 2007-12-17
NZ523189A (en) 2004-08-27
EP1295883A4 (en) 2003-06-11
EE200200698A (et) 2004-08-16
WO2001098300A1 (en) 2001-12-27
SK17682002A3 (sk) 2003-08-05
US6743803B2 (en) 2004-06-01
HUP0301319A2 (hu) 2003-09-29
MXPA02012599A (es) 2003-05-14
EP1295883A1 (en) 2003-03-26
TWI298068B (en) 2008-06-21
NO20026148L (no) 2003-02-20
CN100354274C (zh) 2007-12-12
RU2258506C2 (ru) 2005-08-20
CN1447809A (zh) 2003-10-08
BR0111799A (pt) 2003-05-27
HUP0301319A3 (en) 2008-06-30
PL200537B1 (pl) 2009-01-30
AU6274101A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
IL149924A0 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
GB2368794B (en) Prevention and treatment of amyloidogenic disease
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
HUP0201205A2 (en) Prevention and treatment of amyloidogenic disease
AU6311201A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
HUP0400005A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
PL362920A1 (pl) Kompozycja lecznicza tworząca błonę i układ terapeutyczny zawierający tę kompozycję
HUP0400067A2 (hu) Dementia és neurodegeneratív betegségek kezelése közepes dózisú LHRH-antagonistával
GB0004531D0 (en) The treatment of respiratory diseases
IL153831A (en) Pharmaceutical composition for therapy of neurodegenerative disease of the brain
EP1356812A4 (en) DRUGS FOR TREATING AND PREVENTING NEUROLOGICAL PAIN
AU2002247973A1 (en) Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
IL153439A0 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
PL367634A1 (pl) Kompozycja farmaceutyczna, zawierająca związek trójcykliczny, do profilaktyki i leczenia chorób skóry
HUP0301847A3 (en) Use of adatanserin for producing pharmaceutical compositions for the treatment and prevention of neurodegenerative conditions
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
AU2728301A (en) Combination therapy for the treatment of inflammatory and respiratory diseases

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20100612